Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Wednesday, February 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced its participation in the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The company will present new preclinical study data related to its ARCUS platform, which focuses on developing gene editing therapies for diseases with high unmet needs. This presentation underscores the company's commitment to advancing innovative treatments.
Price reaction · baseline $3.99 (2026-02-17 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing therapies.
  • New preclinical study data indicates progress in research.
  • Presentation at a significant conference highlights company visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Feb. 18, 2026– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data

Frequently Asked Questions

What is the focus of Precision BioSciences' research?

Precision BioSciences focuses on developing in vivo gene editing therapies for diseases with high unmet needs.

When will Precision BioSciences present new data?

The company will present new preclinical study data at the 2026 Muscular Dystrophy Association Conference.

What platform does Precision BioSciences use for gene editing?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing therapies.

Where is the 2026 MDA Conference taking place?

The location of the 2026 Muscular Dystrophy Association Conference is not specified in the article.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing MDA Conference ARCUS platform
Last updated: Feb 18, 2026

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →